What drove Health Care this quarter
S&P 500 · Health Care sector · updated September 21, 2026 · rolling 90-day window
The healthcare sector exhibited a mixed performance this quarter, driven by strong demand for innovative treatments and strategic acquisitions, alongside challenges in specific segments. A notable theme was the robust pipeline of new products, particularly in oncology and immunology, which underpinned Johnson & Johnson's operational growth despite a miss on earnings. The company raised its full-year sales guidance, reflecting confidence in future performance, although it faces risks in its MedTech segment due to procedure volume concerns. Elevance Health also demonstrated resilience, beating earnings expectations and raising its EPS guidance, driven by disciplined execution in Medicare Advantage and Carelon growth, although challenges in Medicaid management remain a concern. In contrast, Biogen's inline results highlighted advancements in Alzheimer's treatment, but the company must navigate regulatory hurdles. Vertex Pharmaceuticals and Moderna both beat expectations, with Vertex's acquisition of Crinetics expected to enhance its growth trajectory, while Moderna's strong demand for mRNA therapies positions it well for future success. Overall, while most companies in the sector showed resilience and positive momentum, the divergence in performance underscores the need for investors to monitor individual company strategies and market dynamics closely.
Health Care companies this quarter
The individual earnings calls behind this synthesis. Each links to the company's full transcript archive — free to read.
In the second quarter of 2026, Johnson & Johnson (JNJ:US) reported strong financial results, with worldwide sales of $25.3 billion, reflecting a 5.6% operational growth. The company also achieved net earnings of $5.5 billion, with diluted E…
In the second quarter of 2026, Elevance Health reported adjusted diluted earnings per share (EPS) of $7.45, exceeding expectations and prompting management to raise full-year EPS guidance to at least $27. Revenue for the quarter was $49.8 b…
In the second quarter of fiscal year 2026, Biogen Inc. reported significant advancements in its Alzheimer's treatment pipeline, particularly with diranersen, which has shown promising results in reducing tau tangles and improving cognitive
In the second quarter of 2026, Vertex Pharmaceuticals announced a definitive agreement to acquire Crinetics Pharmaceuticals for approximately $10 billion, which is expected to enhance Vertex's revenue growth and diversify its portfolio. The…
In the second quarter of fiscal year 2026, Moderna, Inc. reported revenues of $3.5 billion, which exceeded analyst expectations of $3.2 billion, reflecting a 15% year-over-year increase. The company also reported earnings per share (EPS) of…
In the June 25, 2026 earnings call, Merck announced its definitive agreement to acquire Bio-Techne Corporation for USD 73 per share, marking a significant strategic move in the Life Science sector. The acquisition is expected to be immediat…